Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | DCPS | Q96C86 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MPI | P34949 | 1/20 | 0.35 |
| ▸ | SNCA | P37840 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 8/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2244245 | 0.92 | DCPS (0.34) | GRM5DCPSKDM4EL3MBTL1TLR7 | |
| SCHEMBL1775006 | 0.88 | MAPT (0.36) | GRM5TP53MAPTLMNAKDM4E | |
| SCHEMBL2513546 | 0.84 | LMNA (0.33) | GRM5DCPSTP53MAPTLMNA | |
| SCHEMBL4707666 | 0.83 | GRM5 (0.40) | GRM5TP53MAPTLMNAKDM4E | |
| SCHEMBL4792173 | 0.83 | TP53 (0.34) | GRM5DCPSTP53MAPTLMNA | |
| SCHEMBL4792910 | 0.80 | TLR8 (0.37) | GRM5DCPSTP53MAPTLMNA | |
| SCHEMBL4794357 | 0.80 | PIK3CB (0.33) | GRM5DCPSTP53MAPTLMNA | |
| SCHEMBL4707903 | 0.79 | TLR7 (0.37) | TP53MAPTLMNAKDM4EALDH1A1 | |
| SCHEMBL4791809 | 0.79 | POLB (0.39) | GRM5DCPSTP53MAPTLMNA | |
| SCHEMBL4704199 | 0.79 | KCNA5 (0.36) | TP53MAPTLMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207162-B2 | Chiral fused [1,2]imidazo[4,5-c] ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-06-26 | — | — | US | disclosed |
| US-20110207725-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY | 2011-08-25 | — | — | US | disclosed |
| US-7943609-B2 | Such as (tetrahydr)imidazo(4,5-c ) quinoline or naphthymidine; immunomoderators; induce cytokine biosynthesis in animals; anticancer agents; viricides | 3M INNOVATIVE PROPRERTIES COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| EP-1831221-A4 | SUBSTITUTED CHIRAL FUSED 1,2 IMIDAZO 4,5-C RING COMPOUNDS | 3M INNOVATIVE PROPERTIES CO (US) | 2008-11-05 | — | — | EP | disclosed |
| EP-1831226-A4 | CHIRAL FUSED 1,2 IMIDAZO 4,5-c RING COMPOUNDS | 3M INNOVATIVE PROPERTIES CO (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080269192-A1 | Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| EP-1831221-A2 | SUBSTITUTED CHIRAL FUSED 1,2 IMIDAZO 4,5-C RING COMPOUNDS | 3M Innovative Properties Company (US) | 2007-09-12 | — | — | EP | disclosed |
| EP-1831226-A2 | CHIRAL FUSED 1,2 IMIDAZO 4,5-c RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006083440-A2 | SUBSTITUTED CHIRAL FUSED [1,2]IMIDAZO[4,5-C] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006074003-A2 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269192-A1 | Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds | IFNAR1, IFNG, IL4 | GRM5 2061/4885DCPS 3088/4885TP53 339/4885 |
| US-20110207725-A1 | CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | IFNAR1, IFNG, IL4 | GRM5 2061/4885DCPS 3088/4885TP53 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.